

# Yves Pommier

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3883762/yves-pommier-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

252  
papers

22,781  
citations

74  
h-index

147  
g-index

283  
ext. papers

26,307  
ext. citations

10.9  
avg, IF

7.29  
L-index

#	Paper	IF	Citations
252	The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin.. <i>Nature Cell Biology</i> , <b>2022</b> ,	23.4	7
251	Topoisomerase I (TOP1) dynamics: conformational transition from open to closed states.. <i>Nature Communications</i> , <b>2022</b> , 13, 59	17.4	1
250	Human topoisomerases and their roles in genome stability and organization.. <i>Nature Reviews Molecular Cell Biology</i> , <b>2022</b> ,	48.7	7
249	Synthesis of 11-aminoalkoxy substituted benzophenanthridine derivatives as tyrosyl-DNA phosphodiesterase 1 inhibitors and their anticancer activity.. <i>Bioorganic Chemistry</i> , <b>2022</b> , 123, 105789	5.1	1
248	SUMO: A Swiss Army Knife for Eukaryotic Topoisomerases.. <i>Frontiers in Molecular Biosciences</i> , <b>2022</b> , 9, 871161	5.6	1
247	Cancer/Testis Antigen 55 is required for cancer cell proliferation and mitochondrial DNA maintenance.. <i>Mitochondrion</i> , <b>2022</b> , 64, 19-26	4.9	0
246	2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights.. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2022</b> , 37, 349-372	5.6	2
245	From Antarctica to cancer research: a novel human DNA topoisomerase 1B inhibitor from Antarctic sponge <i>Dendrilla antarctica</i> . <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2022</b> , 37, 1404-1410	5.6	0
244	Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy. <i>Cancer Science</i> , <b>2021</b> ,	6.9	2
243	Multiview confocal super-resolution microscopy. <i>Nature</i> , <b>2021</b> , 600, 279-284	50.4	9
242	Functions of the CSB Protein at Topoisomerase 2 Inhibitors-Induced DNA Lesions. <i>Frontiers in Cell and Developmental Biology</i> , <b>2021</b> , 9, 727836	5.7	
241	SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. <i>Cancer Research</i> , <b>2021</b> , 81, 3067-3078	10.1	8
240	Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity. <i>European Journal of Medicinal Chemistry</i> , <b>2021</b> , 215, 113261	6.8	14
239	Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 1338-1349	6.6	1
238	Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. <i>Cancer Cell</i> , <b>2021</b> , 39, 566-579.e7	24.3	24
237	Synthesis of Methoxy-, Methyleneedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer. <i>Journal of Medicinal Chemistry</i> , <b>2021</b> , 64, 7617-7629	8.3	7
236	Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 1431-1441	6.1	10

235	Design and synthesis of C-aryl angular luotonins via a one-pot aza-Nazarov-Friedlander sequence and their Topo-I inhibition studies along with C-aryl vasicinones and luotonins. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2021</b> , 41, 127998	2.9	0
234	Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 478, 569-579	5.1	14
233	An interplay of NOX1-derived ROS and oxygen determines the spermatogonial stem cell self-renewal efficiency under hypoxia. <i>Genes and Development</i> , <b>2021</b> , 35, 250-260	12.6	7
232	Small molecule microarray identifies inhibitors of tyrosyl-DNA phosphodiesterase 1 that simultaneously access the catalytic pocket and two substrate binding sites. <i>Chemical Science</i> , <b>2021</b> , 12, 3876-3884	9.4	7
231	Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	6
230	SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	11
229	PARylation prevents the proteasomal degradation of topoisomerase I DNA-protein crosslinks and induces their deubiquitylation. <i>Nature Communications</i> , <b>2021</b> , 12, 5010	17.4	3
228	Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
227	Genomic and evolutionary classification of lung cancer in never smokers. <i>Nature Genetics</i> , <b>2021</b> , 53, 1348-1359	13.5	14
226	Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway. <i>iScience</i> , <b>2021</b> , 24, 103173	6.1	0
225	Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes. <i>Nucleic Acids Research</i> , <b>2021</b> , 49, 10493-10506	20.1	3
224	Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development. <i>PLoS ONE</i> , <b>2021</b> , 16, e0237554	3.7	7
223	A polymer index-matched to water enables diverse applications in fluorescence microscopy. <i>Lab on A Chip</i> , <b>2021</b> , 21, 1549-1562	7.2	4
222	The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 1589-1597	6.1	5
221	Topoisomerase I-driven repair of UV-induced damage in NER-deficient cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 14412-14420	11.5	8
220	Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC). <i>DNA Repair</i> , <b>2020</b> , 89, 102837	4.3	31
219	Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress. <i>Cell Reports</i> , <b>2020</b> , 30, 4137-4151.e6	10.6	21
218	BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers. <i>Science Translational Medicine</i> , <b>2020</b> , 12,	17.5	43

217	Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 843-859	8.9	26
216	DNA and RNA Cleavage Complexes and Repair Pathway for TOP3B RNA- and DNA-Protein Crosslinks. <i>Cell Reports</i> , <b>2020</b> , 33, 108569	10.6	4
215	Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors. <i>DNA Repair</i> , <b>2020</b> , 85, 102747	4.3	5
214	SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures. <i>Cell Reports</i> , <b>2020</b> , 33, 108296	10.6	32
213	Debulking of topoisomerase DNA-protein crosslinks (TOP-DPC) by the proteasome, non-proteasomal and non-proteolytic pathways. <i>DNA Repair</i> , <b>2020</b> , 94, 102926	4.3	22
212	Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. <i>Oncogene</i> , <b>2020</b> , 39, 5520-5535	9.2	15
211	The first evidence for SLFN11 expression as an independent prognostic factor for patients with esophageal cancer after chemoradiotherapy. <i>BMC Cancer</i> , <b>2020</b> , 20, 1123	4.8	10
210	Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I. <i>Journal of the American Chemical Society</i> , <b>2020</b> , 142, 21178-21188	16.4	5
209	A conserved SUMO pathway repairs topoisomerase DNA-protein cross-links by engaging ubiquitin-mediated proteasomal degradation. <i>Science Advances</i> , <b>2020</b> , 6,	14.3	29
208	MGMT Status as a Clinical Biomarker in Glioblastoma. <i>Trends in Cancer</i> , <b>2020</b> , 6, 380-391	12.5	43
207	Response to Letter to the Editor by Yang et al. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, e91	8.9	
206	BAMscale: quantification of next-generation sequencing peaks and generation of scaled coverage tracks. <i>Epigenetics and Chromatin</i> , <b>2020</b> , 13, 21	5.8	6
205	Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks. <i>Cell Reports</i> , <b>2019</b> , 28, 3167-3181.e6	10.6	53
204	Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening. <i>Nucleic Acids Research</i> , <b>2019</b> , 47, 10134-10150	20.1	18
203	Targeting Topoisomerase I in the Era of Precision Medicine. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6581-6589	2.9	89
202	Mammalian Tyrosyl-DNA Phosphodiesterases in the Context of Mitochondrial DNA Repair. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	4
201	Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2019</b> , 178, 81-92	6.8	8
200	Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity. <i>Molecular Cell</i> , <b>2019</b> , 75, 252-266.e8	17.6	89

199	Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies. <i>Pharmacology &amp; Therapeutics</i> , <b>2019</b> , 201, 94-102	13.9	63
198	Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1. <i>Cancer Research</i> , <b>2019</b> , 79, 2460-2461	10.1	1
197	Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 4669-4682	8.3	8
196	The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , <b>2019</b> , 34, 818-822	5.6	3
195	Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer. <i>Oncogene</i> , <b>2019</b> , 38, 180-193	9.2	23
194	The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6206-6216	12.9	19
193	Beyond the unwinding: role of TOP1MT in mitochondrial translation. <i>Cell Cycle</i> , <b>2019</b> , 18, 2377-2384	4.7	7
192	Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening. <i>Molecules</i> , <b>2019</b> , 24,	4.8	2
191	Identification of Schlafen-11 as a Target of CD47 Signaling That Regulates Sensitivity to Ionizing Radiation and Topoisomerase Inhibitors. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 994	5.3	12
190	Mitochondrial tyrosyl-DNA phosphodiesterase 2 and its TDP2 short isoform. <i>EMBO Reports</i> , <b>2018</b> , 19,	6.5	12
189	SLFN11 Blocks Stressed Replication Forks Independently of ATR. <i>Molecular Cell</i> , <b>2018</b> , 69, 371-384.e6	17.6	115
188	Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( Expression with Class I Histone Deacetylase Inhibitors. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 1944-1953	12.9	42
187	PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, 5601-5617	20.1	33
186	New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2). <i>European Journal of Pharmaceutical Sciences</i> , <b>2018</b> , 118, 67-79 <sup>5.1</sup>		11
185	Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides. <i>European Journal of Pharmaceutical Sciences</i> , <b>2018</b> , 111, 337-348	5.1	12
184	NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5830-5840	12.9	26
183	HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence. <i>Molecules</i> , <b>2018</b> , 23,	4.8	1
182	Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 1694-1704	6.1	22

181	Endogenous single-strand DNA breaks at RNA polymerase II promoters in <i>Saccharomyces cerevisiae</i> . <i>Nucleic Acids Research</i> , <b>2018</b> , 46, 10649-10668	20.1	5
180	Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant gene associated with Angelman syndrome. <i>Molecular Autism</i> , <b>2018</b> , 9, 45	6.5	19
179	TDP1 suppresses mis-joining of radiomimetic DNA double-strand breaks and cooperates with Artemis to promote optimal nonhomologous end joining. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, 8926-8939	20.1	11
178	The evolving landscape of predictive biomarkers of response to PARP inhibitors. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 1727-1730	15.9	32
177	Novel screen for anti-cancer drugs that elevate chromosome instability (CIN) using human artificial chromosome (HAC). <i>Oncotarget</i> , <b>2018</b> , 9, 36833-36835	3.3	2
176	Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 10440-10462	8.3	8
175	CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines. <i>IScience</i> , <b>2018</b> , 10, 247-264	6.1	78
174	Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents. <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 9908-9930	8.3	30
173	Probing the evolutionary conserved residues Y204, F259, S400 and W590 that shape the catalytic groove of human TDP1 for 3Qand 5Qphosphodiester-DNA bond cleavage. <i>DNA Repair</i> , <b>2018</b> , 66-67, 64-74	4.3	3
172	DNA-Targeted Precision Medicine; Have we Been Caught Sleeping?. <i>Trends in Cancer</i> , <b>2017</b> , 3, 2-6	12.5	14
171	A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. <i>Nature Medicine</i> , <b>2017</b> , 23, 461-471	50.5	253
170	Temozolomide in the Era of Precision Medicine. <i>Cancer Research</i> , <b>2017</b> , 77, 823-826	10.1	61
169	Synthesis and Biological Evaluation of the First Triple Inhibitors of Human Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), and Tyrosyl-DNA Phosphodiesterase 2 (Tdp2). <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 3275-3288	8.3	37
168	The NCI-60 Methylome and Its Integration into CellMiner. <i>Cancer Research</i> , <b>2017</b> , 77, 601-612	10.1	34
167	Topoisomerase I-mediated cleavage at unrepaired ribonucleotides generates DNA double-strand breaks. <i>EMBO Journal</i> , <b>2017</b> , 36, 361-373	13	46
166	Effects of camptothecin or TOP1 overexpression on genetic stability in <i>Saccharomyces cerevisiae</i> . <i>DNA Repair</i> , <b>2017</b> , 59, 69-75	4.3	5
165	HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia. <i>Scientific Reports</i> , <b>2017</b> , 7, 12849	4.9	8
164	Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 20162-20172	5.4	13

163	Phosphorylated fraction of H2AX as a measurement for DNA damage in cancer cells and potential applications of a novel assay. <i>PLoS ONE</i> , <b>2017</b> , 12, e0171582	3.7	51
162	Distribution bias and biochemical characterization of TOP1MT single nucleotide variants. <i>Scientific Reports</i> , <b>2017</b> , 7, 8614	4.9	4
161	Genome Organization Drives Chromosome Fragility. <i>Cell</i> , <b>2017</b> , 170, 507-521.e18	56.2	203
160	Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 7315-7332	8.3	26
159	TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 2543-2551	6.1	23
158	Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1). <i>SLAS Discovery</i> , <b>2017</b> , 22, 1093-1105	3.4	12
157	Design and Synthesis of Chlorinated and Fluorinated 7-Azaindenoisoquinolines as Potent Cytotoxic Anticancer Agents That Inhibit Topoisomerase I. <i>Journal of Medicinal Chemistry</i> , <b>2017</b> , 60, 5364-5376	8.3	25
156	Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2116-2126	12.9	19
155	ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair. <i>PLoS ONE</i> , <b>2017</b> , 12, e0188320	3.7	25
154	The dominant role of proofreading exonuclease activity of replicative polymerase $\beta$ in cellular tolerance to cytarabine (Ara-C). <i>Oncotarget</i> , <b>2017</b> , 8, 33457-33474	3.3	14
153	Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. <i>Nature Reviews Molecular Cell Biology</i> , <b>2016</b> , 17, 703-721	48.7	461
152	Small cell lung cancer: Time to revisit DNA-damaging chemotherapy. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 346fs12	17.5	24
151	Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 362ps17	17.5	343
150	top1b, a phylogenetic hallmark gene of Thaumarchaeota encodes a functional eukaryote-like topoisomerase IB. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 2795-805	20.1	4
149	F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death. <i>Future Oncology</i> , <b>2016</b> , 12, 2183-8	3.6	9
148	Chromatin Regulators as a Guide for Cancer Treatment Choice. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1768-77	6.1	15
147	rCellminer: exploring molecular profiles and drug response of the NCI-60 cell lines in R. <i>Bioinformatics</i> , <b>2016</b> , 32, 1272-4	7.2	30
146	HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases. <i>ACS Chemical Biology</i> , <b>2016</b> , 11, 1074-81	4.9	27

145	Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2). <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 2734-46	8.3	37
144	Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons. <i>Bioorganic and Medicinal Chemistry</i> , <b>2016</b> , 24, 1469-79	3.4	18
143	Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. <i>Oncotarget</i> , <b>2016</b> , 7, 76534-76550	3.3	154
142	Analogues of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. <i>Oncotarget</i> , <b>2016</b> , 7, 13984-4001	3.3	26
141	Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 13269-84	3.3	31
140	Parallel analysis of ribonucleotide-dependent deletions produced by yeast Top1 in vitro and in vivo. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 7714-21	20.1	12
139	Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs. <i>Oncotarget</i> , <b>2016</b> , 7, 3084-97	3.3	88
138	Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2016</b> , 35, 56	12.8	18
137	Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 73-81	3.5	24
136	RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription. <i>Cell</i> , <b>2016</b> , 165, 357-71	56.2	142
135	Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons. <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 3840-53	8.3	26
134	Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400). <i>Journal of Medicinal Chemistry</i> , <b>2016</b> , 59, 4890-9	8.3	26
133	Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2. <i>ACS Chemical Biology</i> , <b>2016</b> , 11, 1925-33	4.9	23
132	Selectivity for strand-transfer over 3Q processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 6896-906	20.1	12
131	Novel TDP2-ubiquitin interactions and their importance for the repair of topoisomerase II-mediated DNA damage. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 10201-10215	20.1	15
130	RNA topoisomerase is prevalent in all domains of life and associates with polyribosomes in animals. <i>Nucleic Acids Research</i> , <b>2016</b> , 44, 6335-49	20.1	44
129	Phenanthriplatin Acts As a Covalent Poison of Topoisomerase II Cleavage Complexes. <i>ACS Chemical Biology</i> , <b>2016</b> , 11, 2996-3001	4.9	17
128	Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. <i>DNA Repair</i> , <b>2015</b> , 28, 107-15	4.3	44



127	Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 3841-52	12.9	49
126	Interfacial inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2015</b> , 25, 3961-5	2.9	26
125	Synthesis and biological evaluation of 6-substituted indolizinoquinolinediones as catalytic DNA topoisomerase I inhibitors. <i>European Journal of Medicinal Chemistry</i> , <b>2015</b> , 101, 525-33	6.8	15
124	Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 3997-4015	8.3	34
123	Synthesis and biological evaluation of nitrated 7-, 8-, 9-, and 10-hydroxyindenoisoquinolines as potential dual topoisomerase I (Top1)-tyrosyl-DNA phosphodiesterase I (TDP1) inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 3188-208	8.3	43
122	N-Substituted Quinolinonyl Diketo Acid Derivatives as HIV Integrase Strand Transfer Inhibitors and Their Activity against RNase H Function of Reverse Transcriptase. <i>Journal of Medicinal Chemistry</i> , <b>2015</b> , 58, 4610-23	8.3	29
121	SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4184-93	12.9	65
120	Production of Extrachromosomal MicroDNAs Is Linked to Mismatch Repair Pathways and Transcriptional Activity. <i>Cell Reports</i> , <b>2015</b> , 11, 1749-59	10.6	72
119	Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2015</b> , 112, 11282-7	11.5	37
118	Relative contribution of four nucleases, CtIP, Dna2, Exo1 and Mre11, to the initial step of DNA double-strand break repair by homologous recombination in both the chicken DT40 and human TK6 cell lines. <i>Genes To Cells</i> , <b>2015</b> , 20, 1059-76	2.3	38
117	Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation. <i>Marine Drugs</i> , <b>2015</b> , 13, 3625-39	6	11
116	Topoisomerase I alone is sufficient to produce short DNA deletions and can also reverse nicks at ribonucleotide sites. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 14068-76	5.4	43
115	Anti-HIV-1 activity of a tripodal receptor that recognizes mannose oligomers. <i>European Journal of Medicinal Chemistry</i> , <b>2015</b> , 106, 132-43	6.8	7
114	Single-Molecule Supercoil Relaxation Assay as a Screening Tool to Determine the Mechanism and Efficacy of Human Topoisomerase IB Inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 2552-9	6.1	11
113	Topoisomerase-Induced DNA Cleavage at Ribonucleotide Misincorporation Sites. <i>FASEB Journal</i> , <b>2015</b> , 29, 371.3	0.9	
112	Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 214-20	6.1	96
111	Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 433-43	6.1	459
110	Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2014</b> , 349, 408-16	4.7	179

109	PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. <i>Nucleic Acids Research</i> , <b>2014</b> , 42, 4435-49	20.1	139
108	Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4873-81	12.9	81
107	Biochemical assays for the discovery of TDP1 inhibitors. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 2116-26.1		17
106	Mapping topoisomerase sites in mitochondrial DNA with a poisonous mitochondrial topoisomerase I (Top1mt). <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 18595-602	5.4	16
105	Epigenetic and genetic inactivation of tyrosyl-DNA-phosphodiesterase 1 (TDP1) in human lung cancer cells from the NCI-60 panel. <i>DNA Repair</i> , <b>2014</b> , 13, 1-9	4.3	23
104	Identification of novel PARP inhibitors using a cell-based TDP1 inhibitory assay in a quantitative high-throughput screening platform. <i>DNA Repair</i> , <b>2014</b> , 21, 177-82	4.3	16
103	Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). <i>DNA Repair</i> , <b>2014</b> , 19, 114-29	4.3	192
102	Neuroprotection and repair of 3Qblocking DNA ends by glaikit (gkt) encoding <i>Drosophila</i> tyrosyl-DNA phosphodiesterase 1 (TDP1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 15816-20	11.5	15
101	Proteolytic degradation of topoisomerase II (Top2) enables the processing of Top2DNA and Top2RNA covalent complexes by tyrosyl-DNA-phosphodiesterase 2 (TDP2). <i>Journal of Biological Chemistry</i> , <b>2014</b> , 289, 17960-9	5.4	84
100	Increased negative supercoiling of mtDNA in TOP1mt knockout mice and presence of topoisomerases II and III in vertebrate mitochondria. <i>Nucleic Acids Research</i> , <b>2014</b> , 42, 7259-67	20.1	51
99	Poisoning of mitochondrial topoisomerase I by lamellarin D. <i>Molecular Pharmacology</i> , <b>2014</b> , 86, 193-9	4.3	43
98	ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses. <i>Cancer Research</i> , <b>2014</b> , 74, 6968-79	10.1	110
97	High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. <i>PLoS ONE</i> , <b>2014</b> , 9, e92047	3.7	31
96	Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype. <i>PLoS ONE</i> , <b>2014</b> , 9, e99269	3.7	58
95	The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. <i>Cancer Research</i> , <b>2013</b> , 73, 4372-82	10.1	207
94	Drugging topoisomerases: lessons and challenges. <i>ACS Chemical Biology</i> , <b>2013</b> , 8, 82-95	4.9	569
93	Negative regulation of mitochondrial transcription by mitochondrial topoisomerase I. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, 9848-57	20.1	29
92	TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, 7793-803	20.1	75

91	Biochemical characterization of human tyrosyl-DNA phosphodiesterase 2 (TDP2/TTRAP): a Mg(2+)/Mn(2+)-dependent phosphodiesterase specific for the repair of topoisomerase cleavage complexes. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 30842-52	5.4	50
90	TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1. <i>Nucleic Acids Research</i> , <b>2012</b> , 40, 8371-80	20.1	71
89	Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. <i>Cancer Research</i> , <b>2012</b> , 72, 5588-99	10.1	1186
88	Structural basis for recognition of 5Qphosphotyrosine adducts by Tdp2. <i>Nature Structural and Molecular Biology</i> , <b>2012</b> , 19, 1372-7	17.6	48
87	Mitochondrial topoisomerase I is critical for mitochondrial integrity and cellular energy metabolism. <i>PLoS ONE</i> , <b>2012</b> , 7, e41094	3.7	70
86	Synthesis and biological evaluation of the first dual tyrosyl-DNA phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors. <i>Journal of Medicinal Chemistry</i> , <b>2012</b> , 55, 4457-78	8.3	74
85	Tyrosyl-DNA phosphodiesterase 1 (TDP1) repairs DNA damage induced by topoisomerases I and II and base alkylation in vertebrate cells. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 12848-57	5.4	130
84	A kinetic clutch governs religation by type IB topoisomerases and determines camptothecin sensitivity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 16125-30	11.5	41
83	Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 15030-5	11.5	179
82	Interfacial inhibitors: targeting macromolecular complexes. <i>Nature Reviews Drug Discovery</i> , <b>2011</b> , 11, 25-36	64.1	166
81	Biological evaluation of imidazolium- and ammonium-based salts as HIV-1 integrase inhibitors. <i>MedChemComm</i> , <b>2011</b> , 2, 143-150	5	14
80	Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. <i>Science</i> , <b>2011</b> , 332, 1561-4	33.3	215
79	Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , <b>2011</b> , 21, 1285-92	6.8	68
78	Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. <i>Journal of Cell Biology</i> , <b>2011</b> , 195, 739-49	7.3	120
77	Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC. <i>Nucleic Acids Research</i> , <b>2011</b> , 39, 6620-32	20.1	21
76	Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. <i>Nucleic Acids Research</i> , <b>2011</b> , 39, 3607-20	20.1	111
75	Role of tyrosyl-DNA phosphodiesterase (TDP1) in mitochondria. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 19790-5	11.5	107
74	DNA double-strand breaks and ATM activation by transcription-blocking DNA lesions. <i>Cell Cycle</i> , <b>2010</b> , 9, 274-8	4.7	42

73	Virtual screening using ligand-based pharmacophores for inhibitors of human tyrosyl-DNA phosphodiesterase (hTdp1). <i>Bioorganic and Medicinal Chemistry</i> , <b>2010</b> , 18, 2347-2355	3.4	6
72	DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. <i>Chemistry and Biology</i> , <b>2010</b> , 17, 421-33		1233
71	The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 1008-14	6.1	124
70	Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 18085-95	5.4	96
69	Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA-PK. <i>EMBO Journal</i> , <b>2009</b> , 28, 3667-80	13	110
68	Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. <i>EMBO Reports</i> , <b>2009</b> , 10, 887-93	6.5	176
67	Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. <i>Nature Cell Biology</i> , <b>2009</b> , 11, 1315-24	23.4	351
66	DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. <i>Chemical Reviews</i> , <b>2009</b> , 109, 2894-902	68.1	524
65	CellMiner: a relational database and query tool for the NCI-60 cancer cell lines. <i>BMC Genomics</i> , <b>2009</b> , 10, 277	4.5	165
64	DNA cleavage assay for the identification of topoisomerase I inhibitors. <i>Nature Protocols</i> , <b>2008</b> , 3, 1736-50.8	50.8	85
63	GammaH2AX and cancer. <i>Nature Reviews Cancer</i> , <b>2008</b> , 8, 957-67	31.3	1216
62	Hyperphosphorylation of RNA polymerase II in response to topoisomerase I cleavage complexes and its association with transcription- and BRCA1-dependent degradation of topoisomerase I. <i>Journal of Molecular Biology</i> , <b>2008</b> , 381, 540-9	6.5	49
61	Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2008</b> , 8, 381-9	2.2	113
60	Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition. <i>Biochemical Journal</i> , <b>2008</b> , 411, 523-30	3.8	18
59	Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses. <i>Cancer Research</i> , <b>2007</b> , 67, 8752-61	10.1	84
58	Repair of topoisomerase I-mediated DNA damage. <i>Progress in Molecular Biology and Translational Science</i> , <b>2006</b> , 81, 179-229		213
57	Chk2 molecular interaction map and rationale for Chk2 inhibitors. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2657-61	12.9	76
56	Topoisomerase I inhibitors: camptothecins and beyond. <i>Nature Reviews Cancer</i> , <b>2006</b> , 6, 789-802	31.3	1510

55	Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 2336-45	8.3	373
54	Interfacial inhibition of macromolecular interactions: nature@ paradigm for drug discovery. <i>Trends in Pharmacological Sciences</i> , <b>2005</b> , 26, 138-45	13.2	147
53	Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. <i>Journal of Medicinal Chemistry</i> , <b>2005</b> , 48, 4803-14	8.3	97
52	Integrase inhibitors to treat HIV/AIDS. <i>Nature Reviews Drug Discovery</i> , <b>2005</b> , 4, 236-48	64.1	549
51	Interfacial inhibitors of protein-nucleic acid interactions. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2005</b> , 5, 421-9		60
50	Camptothecins and topoisomerase I: a foot in the door. Targeting the genome beyond topoisomerase I with camptothecins and novel anticancer drugs: importance of DNA replication, repair and cell cycle checkpoints. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , <b>2004</b> , 4, 429-34		78
49	Thirteen-exon-motif signature for vertebrate nuclear and mitochondrial type IB topoisomerases. <i>Nucleic Acids Research</i> , <b>2004</b> , 32, 2087-92	20.1	30
48	Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks. <i>Oncogene</i> , <b>2004</b> , 23, 2934-49	9.2	475
47	Mechanisms of camptothecin resistance by human topoisomerase I mutations. <i>Journal of Molecular Biology</i> , <b>2004</b> , 339, 773-84	6.5	121
46	Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex. <i>Journal of Biological Chemistry</i> , <b>2003</b> , 278, 12461-6	5.4	39
45	Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. <i>Nucleic Acids Research</i> , <b>2002</b> , 30, 1198-204	20.1	102
44	8-Oxoguanine rearranges the active site of human topoisomerase I. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2002</b> , 99, 12102-7	11.5	67
43	Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 13666-72	5.4	33
42	Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 2499-504	12.9	68
41	Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. <i>Journal of Medicinal Chemistry</i> , <b>2001</b> , 44, 3254-63	8.3	159
40	Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. <i>Nature Medicine</i> , <b>2001</b> , 7, 961-6	50.5	290
39	Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. <i>Oncogene</i> , <b>2001</b> , 20, 1852-9	9.2	74
38	Topoisomerase I-mediated DNA damage. <i>Advances in Cancer Research</i> , <b>2001</b> , 80, 189-216	5.9	166

37	Antisense inhibition of Chk2/hCds1 expression attenuates DNA damage-induced S and G2 checkpoints and enhances apoptotic activity in HEK-293 cells. <i>FEBS Letters</i> , <b>2001</b> , 505, 7-12	3.8	56
36	Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors. <i>Annals of the New York Academy of Sciences</i> , <b>2000</b> , 922, 11-26	6.5	53
35	Bay-Region Diol Epoxides of Benzo[a]Pyrene are Stealth Poisons of Topoisomerase I. <i>Polycyclic Aromatic Compounds</i> , <b>2000</b> , 21, 53-62	1.3	
34	A gene expression database for the molecular pharmacology of cancer. <i>Nature Genetics</i> , <b>2000</b> , 24, 236-44	36.3	1173
33	Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2000</b> , 45, 409-16	3.5	11
32	Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 3977-87	4.8	280
31	Mutations in the HIV type 1 integrase of patients receiving long-term dideoxynucleoside therapy do not confer resistance to zidovudine. <i>AIDS Research and Human Retroviruses</i> , <b>2000</b> , 16, 1417-22	1.6	2
30	Substitutions of Asn-726 in the active site of yeast DNA topoisomerase I define novel mechanisms of stabilizing the covalent enzyme-DNA intermediate. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 15246-53	5.4	30
29	The novel silatecan 7-tert-butyl-dimethylsilyl-10-hydroxycamptothecin displays high lipophilicity, improved human blood stability, and potent anticancer activity. <i>Journal of Medicinal Chemistry</i> , <b>2000</b> , 43, 3970-80	8.3	124
28	How do drug-induced topoisomerase I-DNA lesions signal to the molecular interaction network that regulates cell cycle checkpoints, DNA replication, and DNA repair?. <i>Cell Biochemistry and Biophysics</i> , <b>2000</b> , 33, 175-80	3.2	24
27	Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. <i>Nucleic Acids Research</i> , <b>1999</b> , 27, 1919-25	20.1	30
26	Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. <i>Journal of Biological Chemistry</i> , <b>1999</b> , 274, 8516-23	5.4	153
25	Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. <i>International Journal of Cancer</i> , <b>1999</b> , 82, 396-404	7.5	97
24	Topoisomerase I inhibitors: selectivity and cellular resistance. <i>Drug Resistance Updates</i> , <b>1999</b> , 2, 307-318	23.2	141
23	Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. <i>Journal of Medicinal Chemistry</i> , <b>1999</b> , 42, 446-57	8.3	118
22	Early Induction of Apoptosis in Hematopoietic Cell Lines After Exposure to Flavopiridol. <i>Blood</i> , <b>1998</b> , 91, 458-465	2.2	9
21	In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells. <i>Nucleic Acids Research</i> , <b>1997</b> , 25, 4111-6	20.1	23
20	Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 7792-6	5.4	146

19	Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 26441-7	5.4	137
18	Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. <i>Journal of Medicinal Chemistry</i> , <b>1997</b> , 40, 3057-63	8.3	210
17	Ion selective folding of loop domains in a potent anti-HIV oligonucleotide. <i>Biochemistry</i> , <b>1997</b> , 36, 12498-505	3.5	132
16	Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>1997</b> , 40, 433-8	3.5	54
15	DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. <i>Biochemistry</i> , <b>1996</b> , 35, 13303-9	3.2	265
14	Application of the electrotopological state index to QSAR analysis of flavone derivatives as HIV-1 integrase inhibitors. <i>Pharmaceutical Research</i> , <b>1996</b> , 13, 1892-5	4.5	23
13	Cellular resistance to camptothecins. <i>Annals of the New York Academy of Sciences</i> , <b>1996</b> , 803, 60-73	6.5	19
12	DNA recombinase activity of eukaryotic DNA topoisomerase I; effects of camptothecin and other inhibitors. <i>Mutation Research DNA Repair</i> , <b>1995</b> , 337, 135-45		44
11	Cellular pharmacology of azatoxins (topoisomerase-II and tubulin inhibitors) in P-glycoprotein-positive and -negative cell lines. <i>International Journal of Cancer</i> , <b>1995</b> , 63, 268-75	7.5	14
10	Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter elution assay. <i>Drug Development Research</i> , <b>1995</b> , 34, 138-144	5.1	24
9	Apoptosis induced by DNA topoisomerase I and II inhibitors in human leukemic HL-60 cells. <i>Leukemia and Lymphoma</i> , <b>1994</b> , 15, 21-32	1.9	75
8	Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. <i>International Journal of Cancer</i> , <b>1994</b> , 58, 85-94	7.5	15
7	Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. <i>Cancer Investigation</i> , <b>1994</b> , 12, 530-42	2.1	190
6	DNA Topoisomerases and Their Inhibition by Anthracyclines. <i>ACS Symposium Series</i> , <b>1994</b> , 183-203	0.4	7
5	Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. <i>Nucleic Acids Research</i> , <b>1991</b> , 19, 5973-80	20.1	131
4	Nucleosome positioning as a critical determinant for the DNA cleavage sites of mammalian DNA topoisomerase II in reconstituted simian virus 40 chromatin. <i>Nucleic Acids Research</i> , <b>1990</b> , 18, 4553-9	20.1	52
3	Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. <i>Nucleic Acids Research</i> , <b>1990</b> , 18, 6611-9	20.1	169
2	Rapid proteotyping reveals cancer biology and drug response determinants in the NCI-60 cells		3

- 1 A conserved SUMO-Ubiquitin pathway directed by RNF4/SLX5-SLX8 and PIAS4/SIZ1 drives proteasomal degradation of topoisomerase DNA-protein crosslinks

5